PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 29 filers reported holding PHARVARIS N V in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $99,856,146 | +35.5% | 4,784,674 | -1.7% | 11.17% | +47.1% |
| Q2 2023 | $73,713,390 | +287618.1% | 4,868,784 | +53.1% | 7.59% | +137.1% |
| Q1 2023 | $25,620 | -28.4% | 3,180,601 | 0.0% | 3.20% | -19.9% |
| Q4 2022 | $35,782 | -99.9% | 3,180,601 | 0.0% | 4.00% | +37.3% |
| Q3 2022 | $24,395,000 | -65.3% | 3,180,601 | 0.0% | 2.91% | -64.7% |
| Q2 2022 | $70,291,000 | +21.9% | 3,180,601 | 0.0% | 8.24% | +47.1% |
| Q1 2022 | $57,680,000 | +26.0% | 3,180,601 | 0.0% | 5.60% | +54.3% |
| Q4 2021 | $45,769,000 | -18.8% | 3,180,601 | 0.0% | 3.63% | +3.8% |
| Q3 2021 | $56,392,000 | -4.8% | 3,180,601 | 0.0% | 3.50% | -9.9% |
| Q2 2021 | $59,255,000 | -33.4% | 3,180,601 | 0.0% | 3.88% | -23.0% |
| Q1 2021 | $88,993,000 | – | 3,180,601 | – | 5.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,261,926 | $60,770,000 | 8.21% |
| venBio Partners LLC | 2,303,310 | $42,911,000 | 5.06% |
| Bain Capital Life Sciences Investors, LLC | 3,180,601 | $59,255,000 | 3.88% |
| Foresite Capital Management V, LLC | 364,142 | $6,784,000 | 2.67% |
| VR Adviser, LLC | 902,882 | $16,821,000 | 2.04% |
| Cormorant Asset Management, LP | 744,863 | $13,634,000 | 0.46% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,032,757 | $19,240,000 | 0.34% |
| GENERAL ATLANTIC, L.P. | 2,420,155 | $45,087,000 | 0.32% |
| Opaleye Management Inc. | 79,837 | $1,487,000 | 0.25% |
| Avidity Partners Management LP | 400,000 | $7,452,000 | 0.20% |